SMN1 and cystic fibrosis: Although not yet used in clinical applications, this strategy has been successful in in vitro and in vivo models of cystic fibrosis (CF), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), and SMA (Table 2) [130,132].